Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
Hassan discusses how the $14.4 billion Organon acquisition benefits the company as well as other potential M&A areas of interest for Schering-Plough.
You may also be interested in...
Organon/Medarex Expand UltiMab Antibody Agreement To Focus On Novel Target
Firms will codevelop Medarex-identified target, interim CEO Lerner tells “The Pink Sheet” DAILY.
Organon/Medarex Expand UltiMab Antibody Agreement To Focus On Novel Target
Firms will codevelop Medarex-identified target, interim CEO Lerner tells “The Pink Sheet” DAILY.
Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)
Hassan discusses Schering’s late-stage pipeline, including the protease inhibitor boceprevir for hepatitis C and SCH 530348, a thrombin receptor agonist intended as an add-on to Plavix therapy.